Cytek appoints new CFO, reaffirms 2024 financial outlook By Investing.com


© Reuters.

FREMONT, Calif. – Cytek Biosciences, Inc. (NASDAQ:CTKB) announced today the appointment of William (Bill) McCombe as the new chief financial officer. McCombe, with a background as CFO for various technology companies and over 20 years in investment banking, is set to lead Cytek’s global finance activities. His predecessor, Patrik Jeanmonod, has transitioned to head of corporate development analytics.

Cytek, known for its cell analysis solutions, also confirmed its revenue guidance for the full year 2024, projecting $203 million to $213 million, which indicates a 5% to 10% growth over the previous year. The company expects positive net income for the year, assuming stable currency exchange rates.

McCombe’s extensive experience includes roles at Velo3D, HZO, and Maxar Technologies (NYSE:), alongside a significant tenure in investment banking with Morgan Stanley and Bank of America. He holds an MBA from Columbia University and law and commerce degrees from the University of Melbourne.

In his new role, McCombe will oversee accounting, financial planning and analysis, tax, investor relations, internal audit, mergers and acquisitions, and treasury operations. He will be based at Cytek’s headquarters in Fremont, California.

Cytek’s Chairman and CEO, Dr. Wenbin Jiang, expressed confidence in McCombe’s ability to contribute to the company’s sustainable growth and value creation. McCombe himself is eager to join Cytek and is optimistic about its growth potential.

Cytek’s reaffirmation of its 2024 outlook comes amidst a period of strategic growth and financial planning, with the company emphasizing its commitment to delivering high-resolution, high-content, and high-sensitivity cell analysis solutions. The information presented in this article is based on a press release statement from Cytek Biosciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


Source link

Check Also

Investing in W.W. Grainger (NYSE:GWW) five years ago would have delivered you a 275% gain

The worst result, after buying shares in a company (assuming no leverage), would be if …

Leave a Reply

Your email address will not be published. Required fields are marked *